Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of AXL as diagnosis and treatment target of intrauterine adhesion

A technology of intrauterine adhesions and diagnostic markers, applied in the direction of disease diagnosis, medical preparations containing active ingredients, biochemical equipment and methods, etc., can solve problems such as functions that have not been reported, achieve the improvement of endometrial fibrosis, accelerate Intimal fibrosis progression, effects of preventing transdifferentiation

Pending Publication Date: 2022-05-20
NANJING DRUM TOWER HOSPITAL +1
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Through high-throughput sequencing data and experimental verification, we found that AXL is abnormally activated in the tissues of patients with intrauterine adhesions, but its function has not been reported in the endometrium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of AXL as diagnosis and treatment target of intrauterine adhesion
  • Application of AXL as diagnosis and treatment target of intrauterine adhesion
  • Application of AXL as diagnosis and treatment target of intrauterine adhesion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0035] Example 2: Effect of AXL on differentiation of endometrial stromal cells into myofibroblasts.

[0036] 1. Organization, materials, reagents, equipment

[0037] 1.1 Source of human endometrial tissue

[0038] With embodiment 1.

[0039] 1.2 Main reagents

[0040] Collagenase (Sigma), Hyaluronidase (Sigma), DNAase (Roche), DMEM / F12 medium (Gibco), serum (Gibco), primary antibodies (rabbit-derived AXL, phosphorylated AXL, α-SMA and Collagen1) , HRP-labeled anti-rabbit secondary antibody, protein lysate, phosphorylase inhibitor, protease inhibitor, loading buffer, skimmed milk powder.

[0041] 1.3 Main instruments

[0042] Cell incubator, shaker, Western blotting electrophoresis transfer membrane equipment.

[0043] 1.4 Main method

[0044] 1.4.1 Isolation and culture of primary endometrial stromal cells and epithelial cells

[0045]Cut the endometrial tissue with sterile ophthalmic scissors and tweezers until the tissue has no visible lumps, add the prepared digesti...

Embodiment 3

[0051] Example 3: Evaluation of the therapeutic effect of Bemcentinib on endometrial fibrosis of intrauterine adhesions in mice

[0052] 1. Materials, reagents, equipment

[0053] 1.1 Main reagents

[0054] Xylene, ethanol, primary antibody (rabbit source AXL, Collagen 1), goat anti-rabbit FITC fluorescent secondary antibody and goat anti-rabbit PE fluorescent secondary antibody, PBS buffer, DAPI, hematoxylin, Masson check staining solution, acetic acid, phosphomolybdic acid , Aniline blue.

[0055] 1.2 Main instruments

[0056] Incubator, light-proof incubation box, fluorescence microscope

[0057] 1.3 Main method

[0058] 1.3.1 Construction of uterine IUA mouse model:

[0059] The IUA model was established during estrus in SPF grade mice weighing 18-20 g at 9-10 weeks of age, which corresponds to the late proliferative stage in humans, and was confirmed by observation of cell morphology under a vaginal smear microscope. After the mice were anesthetized with isoflurane ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of AXL as a diagnosis and treatment target spot of intrauterine adhesion. It is found that AXL expression in endometrial scar tissue of an intrauterine adhesion patient is remarkably improved, activity is increased, expression of interstitial cells alpha-SMA and Collagen 1 is increased, then transdifferentiation of the interstitial cells to myofibroblasts is promoted, and the endometrial fibrosis process is accelerated. A human primary endometrial interstitial cell experiment and a mouse in-vivo experiment show that transdifferentiation of myofibroblasts can be prevented by applying the Bemcentinib, mouse endometrial fibrosis is improved, and the pregnancy rate and the live baby rate are increased. Therefore, AXL can play an important role in diagnosis of intrauterine adhesion and can be used for diagnosis of diseases. The inhibitor can be applied to medicines for treating intrauterine adhesion.

Description

technical field [0001] The invention belongs to the field of medicaments and relates to the application of AXL as a target for diagnosis and treatment of intrauterine adhesions. Background technique [0002] Intrauterine adhesions (IUA), or Asherman syndrome, is caused by a variety of factors that cause endometrial basal layer damage, functional layer regeneration and repair disorders, and the formation of intramural adhesions characterized by endometrial fibrosis. IUA is the most common cause of uterine infertility, accounting for as high as 25-30% of infertility patients; The incidence of fibrosis was significantly increased. At present, the main diagnosis is to observe the degree of endometrial fibrosis and adhesion under hysteroscopy, and the preferred treatment method is hysteroscopic adhesion dissection, and place intrauterine devices or balloons or biomaterials to block the anterior and posterior walls of the uterus to prevent Re-adhesion. However, hysteroscopic di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883G01N33/573A61K45/00A61K31/501A61P15/00A61P15/08A61P15/06
CPCC12Q1/6883G01N33/573A61K45/00A61K31/501A61P15/00A61P15/08A61P15/06C12Q2600/158G01N2333/912G01N2800/367G01N2800/36
Inventor 胡娅莉赵光锋吕海宁李若天戴建武
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com